FDA Orange Book · active-ingredient family
Vandetanib
Vandetanib is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:CAPRELSA · NDA 022405
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CAPRELSARLD×2 | GENZYME CORP | NDA 022405 | — | Apr 06, 2011 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8067427 | Aug 08, 2028 | in 2 yr 2 mo | Product |
Vandetanib — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
